Bob is the Founder and CEO of DxTerity, a patient-centric genomics company using real-world, longitudinal RNA data to better understand immune-mediated disease. With “from home” access to patients in autoimmune disease and cancer, DxTerity is improving clinical study efficiency while providing a more complete picture of immune response. Bob has over 15 years of experience in the development of revolutionary genomic technologies and products. Bob started out his career at Clinical Micro Sensors, later bought out by Motorola Life Sciences, as the Director of R&D where he oversaw the development of the world’s first bio-electronic DNA detection platform, the e-Sensor. Bob also helped start NanoBiomics to develop genomic tests for the diagnosis and prognosis of cancer that was acquired by the Molecular Profiling Institute before starting DxTerity.
Genomic Monitoring of Lupus Patients. From Home.
From home genomic monitoring of immune-mediated diseases can help provide a better understanding of an individual’s health. The 1300+ lupus participant LIFT study demonstrates the ability to use self-collected fingerstick blood samples mailed from home to cost effectively monitor type 1 interferon levels and T-cell exhaustion markers in lupus.